RVV — Revive Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$6.54m
- CA$6.58m
Annual balance sheet for Revive Therapeutics, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 16.6 | 3.92 | 2.09 | 0.773 | 0.015 |
| Net Total Receivables | 0.127 | 0.191 | 0.157 | 0.021 | 0 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 16.8 | 4.16 | 2.35 | 1.14 | 0.068 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.002 | 0.002 | 0.001 | 0.001 | 0.001 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 29.8 | 17.1 | 14.3 | 10.6 | 0.205 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 0.598 | 4.17 | 3.44 | 3.32 | 3.51 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1 | 4.46 | 3.6 | 3.4 | 3.66 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 28.8 | 12.6 | 10.7 | 7.23 | -3.46 |
| Total Liabilities & Shareholders' Equity | 29.8 | 17.1 | 14.3 | 10.6 | 0.205 |
| Total Common Shares Outstanding |